课题基金 / 基金详情

UNIQUE THIOREDOXIN INHIBITORS AS ANTI-CANCER DRUGS

UNIQUE THIOREDOXIN INHIBITORS AS ANTI-CANCER DRUGS
独特的硫氧还蛋白抑制剂作为抗癌药物
批准号:
6294814
负责人:
LYNN KIRKPATRICK
金额:
$18.89万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-02-01 至 2003-01-31

项目摘要

项目成果

LYNN KIRKPATRICK的其他基金

相似基金

相关文献

中文摘要
翻译
描述:ProlX制药公司已经证明硫氧还蛋白具有
英文摘要
DESCRIPTION: ProlX Pharmaceutical has demonstrated that thioredoxin has an important role in maintaining the transformed phenotype of some human cancers as well as their resistance to chemotherapeutic drugs and is thus a highly rational target for novel cancer drug development. The studies described herein, suggest that thioredoxin is a human anti apoptosis and oncogene that is overexpressed by a number of human cancers. ProlX has exclusive worldwide rights to develop the thioredoxin target and is dedicated to exploiting these observations and rapidly developing agents that selectively disrupt this novel signal transduction pathway. The objective of this Phase I proposal is to develop novel inhibitors of thioredoxin redox system based on a new pharmacophore, identified from the NCI database using ProlX lead compound activities in the 60 cell lines screen and the COMPARE analyses. The Specific Aims of the proposal are 1) to synthesis selective inhibitors of the thioredoxin system using combinatorial chemistry for lead optimization; 2) to investigate the specificity of the compounds for thioredoxin/thioredoxin reductase signaling in vitro; and 3) to evaluated the most active analogues for anti-tumor activity in vivo. These studies will provide novel lead anticancer candidates for further preclinical development, including toxicology, pharmacokinetic studies and the eventual Phase I clinical trial, which will be the subject of a future Phase II application. PROPOSED COMMERCIAL APPLICATION: One is every four deaths in the US is doe to cancer. The overall cancer drug market exceeds $2 billion in the USA. There is significant need to identify novel and selective small molecule- based cancer therapies. This proposal seeks to undertake the synthesis of a chemical library of thioether analogues as potential anticancer drugs, which through thioredoxin inhibition would provide novel therapies against breast, lung, colon and gastric cancer, all which have been found to have elevated thioredoxin levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anticancer redox inhibitor,Pleurotin
  • 批准号:
    6879258
  • 项目类别:
  • 资助金额:
    $19.36万
  • 财政年份:
    2005
  • 负责人:
    LYNN KIRKPATRICK
  • 依托单位:
PI-3 kinase inhibitor PX-866 as anticancer therapy
  • 批准号:
    7159438
  • 项目类别:
  • 资助金额:
    $79.09万
  • 财政年份:
    2005
  • 负责人:
    LYNN KIRKPATRICK
  • 依托单位:
PI-3 kinase inhibitor PX-866 as anticancer therapy
  • 批准号:
    6932660
  • 项目类别:
  • 资助金额:
    $19.12万
  • 财政年份:
    2005
  • 负责人:
    LYNN KIRKPATRICK
  • 依托单位:
PI-3 kinase inhibitor PX-866 as anticancer therapy
  • 批准号:
    7263198
  • 项目类别:
  • 资助金额:
    $83.58万
  • 财政年份:
    2005
  • 负责人:
    LYNN KIRKPATRICK
  • 依托单位:
海外基金